Incyte Corporation (INCY)
- Previous Close
52.72 - Open
52.96 - Bid 52.82 x 100
- Ask 52.89 x 100
- Day's Range
52.26 - 53.10 - 52 Week Range
50.27 - 75.74 - Volume
1,787,018 - Avg. Volume
1,702,632 - Market Cap (intraday)
11.859B - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
19.93 - EPS (TTM)
2.65 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
75.35
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
www.incyte.comRecent News: INCY
Performance Overview: INCY
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INCY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INCY
Valuation Measures
Market Cap
11.86B
Enterprise Value
8.24B
Trailing P/E
19.93
Forward P/E
11.16
PEG Ratio (5yr expected)
0.68
Price/Sales (ttm)
3.23
Price/Book (mrq)
2.28
Enterprise Value/Revenue
2.23
Enterprise Value/EBITDA
8.96
Financial Highlights
Profitability and Income Statement
Profit Margin
16.17%
Return on Assets (ttm)
6.46%
Return on Equity (ttm)
12.50%
Revenue (ttm)
3.7B
Net Income Avi to Common (ttm)
597.6M
Diluted EPS (ttm)
2.65
Balance Sheet and Cash Flow
Total Cash (mrq)
3.66B
Total Debt/Equity (mrq)
1.01%
Levered Free Cash Flow (ttm)
610.78M
Research Analysis: INCY
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: INCY
Mid Cap U.S. Pick List April 2024
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.
The Argus Mid-Cap Model Portfolio
Small- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.
Mid Cap U.S. Pick List March 2024
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.
Analyst Report: Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
RatingBullishPrice Target